drugset / Trial / NCT06641895
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy
Phase 0
Recruiting
6 enrolled
Shanghai Jiao Tong University School of Medicine
Shanghai Mianyi Biopharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety, tolerability, and efficacy of BBM-D101 to treat patients with Duchenne Muscular Dystrophy.
Timeline
- Start
- 2024-07-25
- Primary completion
- 2026-07-31
- Completion
- 2030-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BBM-D101 | Gene therapy (AAV / viral vector) | — | Intravenous |